Transcenta Holding Limited (HKG:6628)
Hong Kong · Delayed Price · Currency is HKD 2.130
+0.010 (0.47%)
May 7, 2026, 4:08 PM HKT
Transcenta Holding Revenue
In the year 2025, Transcenta Holding had annual revenue of 7.44M CNY, down -33.98%. Transcenta Holding had revenue of 4.72M in the half year ending December 31, 2025, a decrease of -73.41%.
Revenue
7.44M CNY
Revenue Growth
-33.98%
P/S Ratio
115.82
Revenue / Employee
47.97K CNY
Employees
155
Market Cap
958.27M HKD
Revenue Chart
* This company reports financials in CNY.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 7.44M | -3.83M | -33.98% |
| Dec 31, 2024 | 11.26M | -42.59M | -79.09% |
| Dec 31, 2023 | 53.85M | -48.04M | -47.15% |
| Dec 31, 2022 | 101.89M | 51.65M | 102.80% |
| Dec 31, 2021 | 50.24M | -30.74M | -37.96% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Uni-Bio Science Group | 586.21M |
| 3D Medicines | 396.26M |
| JW (Cayman) Therapeutics Co. | 315.65M |
| Wuhan YZY Biopharma | 74.40M |
| CANbridge Pharmaceuticals | 55.62M |
| Shanghai Bio-heart Biological Technology | 50.00M |
| Brii Biosciences | 39.56M |
| Beijing Biostar Pharmaceuticals | 37.13M |
Transcenta Holding News
- 4 months ago - Transcenta Collaborates With EirGenix To License HiCB Platform - Nasdaq